Related Experiment Video

Updated: Mar 18, 2026

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

11.6K

Recent progress in development of siRNA delivery vehicles for cancer therapy

Hyun Jin Kim1, Ahram Kim2, Kanjiro Miyata1

  • 1Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

Advanced Drug Delivery Reviews
|June 30, 2016
PubMed

Insights

RNA drugs show promise for cancer therapy but require delivery vehicles for stability and targeted delivery. This review covers clinical trials and design strategies for effective small interfering RNA (siRNA) delivery systems.

Area of Science:

  • RNA biology
  • Cancer therapy
  • Drug delivery systems

Background:

  • RNA drugs, particularly small interfering RNAs (siRNAs), offer new therapeutic avenues for cancer.
  • siRNAs face challenges including rapid degradation by RNases and renal filtration, necessitating effective delivery systems.
  • Current delivery strategies involve cationic lipids, polymers, and nanoparticles for systemic siRNA delivery to solid tumors.

Purpose of the Study:

  • To review the current clinical trial status of siRNA-based cancer therapies.
  • To identify challenges hindering the success of siRNA cancer therapies.
  • To introduce innovative design strategies for stable and targeted siRNA delivery vehicles.

Main Methods:

  • Literature review of clinical trials in siRNA cancer therapy.
  • Analysis of existing and emerging delivery vehicle formulations for siRNA.
  • Discussion of design principles for enhanced stability and targeting of siRNA.

Main Results:

  • The review details the progress and limitations of ongoing clinical trials for siRNA cancer treatments.
  • Various delivery systems, including lipid-based, polymeric, and nanoparticle formulations, are evaluated.
  • Promising design strategies for overcoming siRNA instability and achieving targeted delivery are presented.

Conclusions:

  • Effective delivery systems are crucial for the clinical success of siRNA cancer therapeutics.
  • Continued innovation in delivery vehicle design is essential for stable, targeted, and efficient siRNA delivery.
  • Addressing current challenges will pave the way for advanced siRNA-based cancer therapies.
Keywords:
Cancer therapyPolyion complex micelleRNAiSystemic administrationsiRNA delivery

More Related Videos

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

8.0K
Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery08:53

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Published on: April 16, 2019

8.3K

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.2K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
82